生物标志物在脑淀粉样病变诊治中的应用进展  

Application progress of biomarkers in the diagnosis and treatment of cerebral amyloidosis

作　　者：格力班 王忠 GE Liban;WANG Zhong(Baotou Graduate School of Medicine,Inner Mongolia University of Science and Technology,Inner Mongolia Autonomous Region,Baotou 014040,China;Department of Neurosurgery,Inner Mongolia Autonomous Region People’s Hospital,Inner Mongolia Autonomous Region,Hohhot 010017,China)

机构地区：[1]内蒙古科技大学包头医学研究生院,内蒙古包头014040 [2]内蒙古自治区人民医院神经外科,内蒙古呼和浩特010017

出　　处：《中国医药导报》2024年第23期61-65,共5页China Medical Herald

基　　金：内蒙古自治区卫生健康科技计划项目(202201059)。

摘　　要：脑淀粉样血管病是一种脑血管疾病,其特征是淀粉样蛋白在软脑膜和脑皮质中小血管内积聚。神经影像学技术的进步使脑淀粉样血管病的生前诊断成为目前世界范围内应用最广泛的检查措施。然而,神经影像学在早期脑淀粉样血管病的检测中准确性有限,近年来许多研究均在寻找诊断早期淀粉样血管病的可靠生物标志物,将有助于早期脑淀粉样血管病的诊断,确保早发现、早诊断和早治疗。本文主要综述生物标志物在脑淀粉样病变诊治中的应用进展。Cerebral amyloid angiopathy is a cerebrovascular disease.It is characterized by the accumulation of amyloid in small blood vessels in leptomeninges and cerebral cortex.Advance in neuroimaging technology has made prenatal diagnosis of cerebral amyloid angiopathy the most widely used test in the world.However,the accuracy of neuroimaging in the detection of early cerebral amyloid angiopathy is limited,and many studies in recent years have been looking for reliable biomarkers in the diagnosis of early amyloid angiopathy,which will help in early diagnosis of cerebral amyloid angiopathy and ensure early detection,early diagnosis,and early treatment.This article reviews application progress of biomarkers in the diagnosis and treatment of cerebral amyloidosis.

关 键 词：脑淀粉样血管病 生物标志物 Β淀粉样蛋白 

分 类 号：R743[医药卫生—神经病学与精神病学]